Chronic Hepatitis B Infection and Pregnancy
Authors:
- Michelle L. GilesMGMichelle L. Giles
- Kumar VisvanathanKVKumar Visvanathan
- Sharon R. LewinSharon R. Lewin
- Joe SasadeuszJSJoe Sasadeusz
- 1 January 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (1) , 37-44
Abstract
It is estimated that 350 to 400 million individuals worldwide are chronically infected with hepatitis B virus (HBV). In regions of high endemicity, many of these are females of reproductive age who are an important source for perinatal transmission. There are a number of issues specific to the women of childbearing age who have chronic HBV infection, including the safety of antiviral therapy during pregnancy and breast-feeding, the changes in the immune system during pregnancy and postpartum that may impact on the natural history of HBV, and the emerging role of antivirals to reduce perinatal transmission of HBV. For women in their reproductive years who require treatment, many of the available antivirals have not been studied in pregnant or breast-feeding women and their use requires the development of a carefully considered strategy, considering the impact of both the disease and treatment on the mother and fetus/infant. The purpose of this article is to (1) review data regarding the mechanisms and timing of perinatal HBV infection; (2) review data on interventions, particularly antiviral therapy, to reduce perinatal transmission beyond the protection afforded by hepatitis B immunoglobulin and vaccination; (3) summarize the immunological changes associated with pregnancy and the potential effect these may have on the natural history of HBV infection; and (4) summarize the information currently available for antiviral therapy available for HBV treatment, focusing specifically on safety data pertaining to reproduction, pregnancy, and breast-feeding. Obstetricians & Gynecologists and Family Physicians. After completing this CME activity physicians should be better able to classify the interventions to reduce mother-to-child transmission of hepatitis B including antivirals, caesarean section, hepatitis B immunoglobulin and hepatitis B vaccine, assess the immunological changes associated with pregnancy and the potential effect this may have on the natural history of HBV infection and apply the information currently available for antiviral therapy licensed for HBV treatment, focusing specifically on safety data in pregnancy and during breastfeeding.Keywords
This publication has 61 references indexed in Scilit:
- Lamivudine in Late Pregnancy to Interrupt In Utero Transmission of Hepatitis B VirusObstetrics & Gynecology, 2010
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Source of transmission in children with chronic hepatitis B infection after the implementation of a strategy for prevention in those at high riskHepatology Research, 2009
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus – a systematic reviewVirology Journal, 2008
- Hepatitis B virus infections in families in which the mothers are negative but the fathers are positive for HBsAgHepatology Research, 2006
- Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trialThe Lancet, 2002
- Letters to the EditorJournal of Hepatology, 2000
- Food-Related Illness and Death in the United StatesEmerging Infectious Diseases, 1999
- Phenotypic and functional evaluation of suppressor cells in normal pregnancy and in chronic abortersCellular Immunology, 1986